EKSO trades 74.4% above Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EKSO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Ekso Bionics Holdings, Inc. (EKSO) has a Wall Street consensus price target of $6.00, based on estimates from 4 covering analysts. With the stock currently trading at $23.45, this represents a potential downside of -74.4%. The company has a market capitalization of $57M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EKSO trades at a trailing P/E of -4.8x. Analysts expect EPS to grow +97.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
IRBTiRobot Corporation | $2M | $0.05 | — | — | — | — | — |
CYBRCyberArk Software Ltd. | $20.6B | $408.85 | $447.00 | +9.3% | Buy | 81.9x | 49 |
ATAIAtai Beckley N.V | $1.5B | $4.06 | $12.00 | +195.6% | Buy | — | 4 |
MYOMyomo, Inc. | $49M | $1.28 | — | — | — | — | — |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
GMEDGlobus Medical, Inc. | $10.7B | $79.23 | $109.50 | +38.2% | Buy | 16.7x | 36 |
ISRGIntuitive Surgical, Inc. | $144.5B | $406.78 | $597.78 | +47.0% | Buy | 38.9x | 55 |
MASIMasimo Corporation | $9.4B | $179.95 | $180.00 | +0.0% | Buy | 32.7x | 23 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
Quick answers to the most common questions about buying EKSO stock.
EKSO's consensus price target is $6, -74.4% below the current price of $23.45. The 4 analysts tracking EKSO see downside risk at present valuations.
EKSO has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies -74.4% downside from current levels.
EKSO's current price is $23.45 with a consensus target of $6 (-74.4% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for EKSO, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
EKSO is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EKSO stock forecast based on 4 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Analysts are cautious on EKSO, with 0 Sell ratings and a price target of $6 (-74.4% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EKSO analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.